Current evidence for pharmacologic therapy following stage 1 palliation for single ventricle congenital heart disease

References

• Ohye RG, Schranz D, D’Udekem Y. Current therapy for hypoplastic left heart syndrome and related single ventricle lesions. Circulation. 2016;134(17):1265–1279.
   PubMed Web of Science ®Google Scholar
• Schilling C, Dalziel K, Nunn R, et al. The Fontan epidemic: population projections from the Australia and New Zealand Fontan registry. Int J Cardiol. 2016;219:14–19.
   PubMedGoogle Scholar
• Hirsch JC, Goldberg C, Bove EL, et al. Fontan operation in the current era: a 15-year single institution experience. Ann Surg. 2008;248(3):402–410.
   PubMed Web of Science ®Google Scholar
• Ghanayem NS, Allen KR, Tabbutt S, et al. Interstage mortality after the Norwood procedure: results of the multicenter Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg. 2012;144(4):896–906.
   PubMed Web of Science ®Google Scholar
• Gewillig M. The Fontan circulation. Heart. 2005;91(6):839–846.
   PubMed Web of Science ®Google Scholar
• Cross RR, Harahsheh AS, McCarter R, et al. Collaborative (NPC-QIC NPCQI. Identified mortality risk factors associated with presentation, initial hospitalisation, and interstage period for the Norwood operation in a multi-centre registry: a report from the National Pediatric Cardiology-Quality Improvement Collaborative. Cardiol Young. 2014;24(2):253–262.
   PubMedGoogle Scholar
• Simsic JM, Bradley SM, Stroud MR, et al. Risk factors for interstage death after the Norwood procedure. Pediatr Cardiol. 2005;26(4):400–403.
   PubMedGoogle Scholar
• Hehir DA, Dominguez TE, Ballweg JA, et al. Risk factors for interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variants. J Thorac Cardiovasc Surg. 2008;136(1):94–99. e3.
   PubMedGoogle Scholar
• Rudd NA, Ghanayem NS, Hill GD, et al. Interstage home monitoring for infants with single ventricle heart disease: education and management: a scientific statement from the American Heart Association. J Am Heart Assoc. 2020;9(16):e014548.
   PubMedGoogle Scholar
• Schidlow DN, Anderson JB, Klitzner TS, et al. Variation in interstage outpatient care after the Norwood procedure: a report from the joint council on congenital heart disease national quality improvement collaborative. Congenit Heart Dis. 2011;6(2):98–107.
   PubMedGoogle Scholar
• Kaltman JR, Andropoulos DB, Checchia PA, et al. Report of the pediatric heart network and national heart, lung, and blood institute working group on the perioperative management of congenital heart disease. Circulation. 2010;121(25):2766–2772.
   PubMedGoogle Scholar
• Anderson JB, Brown DW, Lihn S, et al. Power of a learning network in congenital heart disease. World J Pediatr Congenit Heart Surg. 2019;10(1):66–71.
   PubMedGoogle Scholar
• National Pediatric Cardiology Quality Improvement Collaborative. http://npcqic.org. Accessed 2021 Dec 9.
   Google Scholar
• Anderson JB, Brown DW, Horsley M, et al. Reduction in interstage growth failure in infants with hypoplastic left heart syndrome and impact on stage 2 outcomes: a report from the national pediatric cardiology quality improvement collaborative. J Am Coll Cardiol. 2017;69(11):584.
   Google Scholar
• Tweddell JS, Hoffman GM, Fedderly RT, et al. Phenoxybenzamine improves systemic oxygen delivery after the Norwood procedure. Ann Thorac Surg. 1999;67(1):161–167.
   PubMedGoogle Scholar
• Guzzetta NA. Phenoxybenzamine in the treatment of hypoplastic left heart syndrome: a core review. Anesth Analg. 2007;105(2):312–315.
   PubMedGoogle Scholar
• Mills KI, Kaza AK, Walsh BK, et al. Phosphodiesterase inhibitor‐based vasodilation improves oxygen delivery and clinical outcomes following stage 1 palliation. J Am Heart Assoc. 2016;5(11):e003554.
   PubMedGoogle Scholar
• Hoffman GM, Tweddell JS, Ghanayem NS, et al. Alteration of the critical arteriovenous oxygen saturation relationship by sustained afterload reduction after the Norwood procedure. J Thorac Cardiovasc Surg. 2004;127(3):738–745.
   PubMedGoogle Scholar
• Hoffman GM, Niebler RA, Scott JP, et al. Interventions associated with treatment of low cardiac output after stage 1 Norwood palliation. Ann Thorac Surg. 2021;111(5):1620–1627.
   PubMedGoogle Scholar
• Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–1420.
   PubMed Web of Science ®Google Scholar
• Mori Y, Nakazawa M, Tomimatsu H, et al. Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol. 2000;36(1):270–275.
   PubMedGoogle Scholar
• Calabrò R, Pisacane C, Pacileo G, et al. Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation. Am Heart J. 1999;138(5):955–961.
   PubMedGoogle Scholar
• Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. Arch Dis Child. 1988;63(4):360–363.
   PubMedGoogle Scholar
• Balaguru D, Artman M, Auslender M. Management of heart failure in children. Curr Probl Pediatr. 2000;30(1):5–30.
   Google Scholar
• Group CTS. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429–1435.
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S; for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Jama. 1995;273(18):1450–1456.
   PubMed Web of Science ®Google Scholar
• Hsu DT, Zak V, Mahony L, et al., Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation. 122(4): 333–340. 2010.
   PubMed Web of Science ®Google Scholar
• Yimgang DP, Sorkin JD, Evans CF, et al. Angiotensin converting enzyme inhibitors and interstage failure in infants with hypoplastic left heart syndrome. Congenit Heart Dis. 2018;13(4):533–540.
   PubMedGoogle Scholar
• Zak V, Hsu DT, Pemberton VL, et al. Translating clinical trials into clinical practice: a survey assessing the potential impact of the pediatric heart network infant single ventricle trial. Cardiol Young. 2017;27(7):1265–1270.
   PubMedGoogle Scholar
• Hansen JE, Brown DW, Hanke SP, et al., Angiotensin 2010; converting enzyme inhibitor prescription for patients with single ventricle physiology enrolled in the NPC 2010;QIC registry. J Am Heart Assoc. 9(10): e014823. 2020.
   PubMedGoogle Scholar
• Mathur K, Hsu DT, Lamour JM, et al. Safety of enalapril in infants: data from the pediatric heart network infant single ventricle trial. J Pediatr. 2020;227:218–223.
   PubMedGoogle Scholar
• Mital S, Chung WK, Colan SD, et al. Pediatric Heart Network Investigators. Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. Circulation. 2011;123(21):2353–2362.
   PubMedGoogle Scholar
• Jain S, Vaidyanathan B. Digoxin in management of heart failure in children: should it be continued or relegated to the history books? Ann Pediatr Cardiol. 2009;2(2):149.
   PubMedGoogle Scholar
• Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993;22(4):955–962.
   PubMed Web of Science ®Google Scholar
• Group DI. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533.
   PubMedGoogle Scholar
• Ziff OJ, Lane DA, and Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.
   PubMed Web of Science ®Google Scholar
• Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. Jama. 2003;289(7):871–878.
   PubMed Web of Science ®Google Scholar
• Kimball TR, Daniels SR, Meyer RA, et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol. 1991;68(13):1377–1382.
   PubMedGoogle Scholar
• Berman JW, Yabek SM, Dillon T, et al. Effects of digoxin in infants with a congested circulatory state due to a ventricular septal defect. N Engl J Med. 1983;308(7):363–366.
   PubMedGoogle Scholar
• Seguchi M, Nakazawa M, Momma K. Further evidence suggesting a limited role of digitalis in infants with circulatory congestion secondary to large ventricular septal defect. Am J Cardiol. 1999;83(9):1408–1411.
   PubMedGoogle Scholar
• O’Byrne ML, Song L, Huang J, et al. Trends in discharge prescription of digoxin after Norwood operation: an analysis of data from the Pediatric Health Information System (PHIS) database. Pediatr Cardiol. 2021;42(4):793–803.
   PubMedGoogle Scholar
• Brown DW, Mangeot C, Anderson JB, et al. Digoxin use is associated with reduced interstage mortality in patients with no history of arrhythmia after stage I palliation for single ventricle heart disease. J Am Heart Assoc. 2016;5(1):e002376.
   PubMedGoogle Scholar
• Oster ME, Kelleman M, McCracken C, et al. Association of digoxin with interstage mortality: results from the pediatric heart network single ventricle reconstruction trial public use dataset. J Am Heart Assoc. 2016;5(1):e002566.
   PubMedGoogle Scholar
• Truong DT, Menon SC, Lambert LM, et al., Digoxin use in infants with single ventricle physiology: secondary analysis of the pediatric heart network infant single ventricle trial public use dataset. Pediatr Cardiol. 39(6): 1200–1209. 2018.
   PubMedGoogle Scholar
• National Pediatric Cardiology Quality Improvement Collaborative. Phase II: measure Definitions. NPCQIC Reporting - Measure Definitions, Cincinnati Children’s Hospital Medical Center, 2018, reports.npcqic.org/reports/phase2/measure_definitions.xhtml.
   Google Scholar
• Simsic JM, Cuadrado A, Kirshbom PM, et al. Novel management strategy for severe cyanosis after Sano modification of the Norwood procedure. J Thorac Cardiovasc Surg. 2005;129(6):1450–1451.
   PubMedGoogle Scholar
• Kumar KR, Flair A, Thompson EJ, et al. Association between digoxin use and cardiac function in infants with single-ventricle congenital heart disease during the interstage period. Pediatr Crit Care Med. 2022Apr11; 23(6)453–463. published online ahead of print.
   PubMedGoogle Scholar
• Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80(11A):26L–40L.
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Boucek MM, Hsu DT, et al., Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 298(10): 1171–1179. 2007.
   PubMed Web of Science ®Google Scholar
• Miyamoto SD, Stauffer BL, Polk J, et al. Gene expression and β-adrenergic signaling are altered in hypoplastic left heart syndrome. J Heart Lung Transplant. 2014;33(8):785–793.
   PubMedGoogle Scholar
• Szwarc E, Rodrigues MH, Pedra SF, et al. Use of beta-blockers in the post-operative period of Sano modification of the Norwood procedure with persistent cyanosis. Arq Bras Cardiol. 2007;88(6):e182–e184.
   PubMedGoogle Scholar
• Mienert T, Esmaeili A, Steinbrenner B, et al. Cardiovascular drug therapy during interstage after hybrid approach: a single-center experience in 51 newborns with hypoplastic left heart. Pediatr Drugs. 2021;23(2):195–202.
   PubMedGoogle Scholar
• Oster ME, Chen S, Dagincourt N, et al. Development and impact of arrhythmias after the Norwood procedure: a report from the Pediatric Heart Network. J Thorac Cardiovasc Surg. 2017;153(3):638–645. e2.
   PubMedGoogle Scholar
• Moffett BS, Mattamal R, Ocampo EC, et al. Impact of pharmacotherapy on interstage outcomes in single ventricle infants. Congenit Heart Dis. 2011;6(4):286–293.
   PubMedGoogle Scholar
• Ghelani SJ, Spurney CF, Martin GR, et al. Impact of pharmacotherapy on interstage mortality and weight gain in children with single ventricle. Congenit Heart Dis. 2013;8(3):219–227.
   PubMedGoogle Scholar
• Agarwal A, Firdouse M, Brar N, et al. Incidence and management of thrombotic and thromboembolic complications following the Norwood procedure: a systematic review. Clin Appl Thromb. 2017;23(8):911–921.
   PubMedGoogle Scholar
• White MH, Kelleman M, Sidonio RF, et al. Incidence and timing of thrombosis after the Norwood procedure in the single‐ventricle reconstruction trial. J Am Heart Assoc. 2020;9(24):e015882.
   PubMedGoogle Scholar
• Manlhiot C, Brandão LR, Kwok J, et al. Thrombotic Complications and Thromboprophylaxis Across All Three Stages of Single Ventricle Heart Palliation. J Pediatr. https://www.jpeds.com/article/S0022-3476(12)00260-0/fulltext. Accessed 2021 Nov 15.
   Google Scholar
• Silvey M, Hall M, Bilynsky E, et al. Increasing rates of thrombosis in children with congenital heart disease undergoing cardiac surgery. Thromb Res. 2018;162:15–21.
   PubMed Web of Science ®Google Scholar
• Gedicke M, Morgan G, Parry A, et al. Risk factors for acute shunt blockage in children after modified Blalock-Taussig shunt operations. Heart Vessels. 2010;25(5):405–409.
   PubMedGoogle Scholar
• Do N, Hill KD, Wallace AS, et al. Shunt failure—risk factors and outcomes: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg. 2018;105(3):857–864.
   PubMedGoogle Scholar
• Li JS, Yow E, Berezny KY, et al. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? Circulation. 2007;116(3):293–297.
   PubMedGoogle Scholar
• Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2013;128(24):2622–2703.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, King E, Nebbia A, et al. Variability of antithrombotics use in patients with hypoplastic left heart syndrome and its variants following first-and second-stage palliation surgery: a national report using the National Pediatric Cardiology Quality Improvement Collaborative registry. Cardiol Young. 2017;27(4):731–738.
   PubMedGoogle Scholar
• Truong DT, Johnson JT, Bailly DK, et al. Platelet inhibition in shunted infants on aspirin at short and midterm follow-up. Pediatr Cardiol. 2017;38(2):401–409.
   PubMedGoogle Scholar
• Mir A, Frank S, Journeycake J, et al. Aspirin resistance in single-ventricle physiology: aspirin prophylaxis is not adequate to inhibit platelets in the immediate postoperative period. Ann Thorac Surg. 2015;99(6):2158–2164.
   PubMedGoogle Scholar
• Emani S, Zurakowski D, Mulone M, et al. Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery. J Thorac Cardiovasc Surg. 2017;154(5):1723–1730.
   PubMed Web of Science ®Google Scholar
• Saini A, Joshi AD, Cowan KM, et al. High acetylsalicylic acid dosing in infants after modified Blalock–Taussig shunt. Cardiol Young. 2019;29(3):389–397.
   PubMedGoogle Scholar
• Wessel DL, Berger F, Li JS, et al. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med. 2013;368(25):2377–2384.
   PubMedGoogle Scholar
• Young G, Lensing AW, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation. J Thromb Haemost. 2020;18(7):1672–1685.
   PubMed Web of Science ®Google Scholar
• Heo JH, Rascati KL, Lopez KN, et al. Increased fracture risk with furosemide use in children with congenital heart disease. J Pediatr. 2018;199:92–98.e10.
   PubMedGoogle Scholar
• Saarela T, Lanning P, Koivisto M, et al. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up. Eur J Pediatr. 1999;158(8):668–672.
   PubMedGoogle Scholar
• Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr. 1994;125(1):149–151.
   PubMedGoogle Scholar
• Robertson CM, Alton GY, Bork KT, et al. Bilateral sensory permanent hearing loss after palliative hypoplastic left heart syndrome operation. Ann Thorac Surg. 2012 Apr;93(4):1248–1253.
   PubMedGoogle Scholar
• Robertson CMT, Bork KT, Tawfik G. Avoiding furosemide ototoxicity associated with single-ventricle repair in young infants. Pediatr Crit Care Med. 2019;20(4):350–356.
   PubMedGoogle Scholar
• Zheng H, Li L, Liang H, et al. Normalization of N-terminal pro-B-type natriuretic peptide after cardiac surgery among children with tetralogy of Fallot. Am J Cardiol. 2018;122(12):2125–2130.
   PubMedGoogle Scholar
• Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123(11):1185–1193.
   PubMed Web of Science ®Google Scholar
• Garcia AM, Nakano SJ, Karimpour-Fard A, et al. Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro. Circ Heart Fail. 2018 Sep;11(9):e004571.
   PubMed Web of Science ®Google Scholar
• Jeremiasen I, Tran-Lundmark K, Idris N, et al. Pulmonary vasodilator therapy in children with single ventricle physiology: effects on saturation and pulmonary arterial pressure. Pediatr Cardiol. 2020 Dec;41(8):1651–1659.
   PubMedGoogle Scholar
• Handler SS, Ogawa MT, Hopper RK, et al. Subcutaneous treprostinil in pediatric patients with failing single-ventricle physiology. J Heart Lung Transplant. 2017. DOI:10.1016/j.healun.2017.09.008
   PubMedGoogle Scholar
• van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925–935.
   PubMed Web of Science ®Google Scholar
• Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–520. e4.
   PubMed Web of Science ®Google Scholar
• Wang Y-H, Wintzell V, Ludvigsson JF, et al. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatr. 2020;174(6):543–551.
   PubMedGoogle Scholar
• Wang YH, Wintzell V, Ludvigsson JF, et al. Association between proton pump inhibitor use and risk of asthma in children. JAMA Pediatr. 2021;175(4):394–403.
   PubMedGoogle Scholar
• van der Pol R, Langendam M, Benninga M, et al. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 2014;168(10):947–954.
   PubMed Web of Science ®Google Scholar
• Tighe M, Afzal NA, Bevan A, et al. Pharmacological treatment of children with gastro‐oesophageal reflux. Cochrane Database Syst Rev. 2014 11;2016(11). DOI:10.1002/14651858.CD008550.pub2
   Google Scholar
• Ohye RG, Schonbeck JV, Eghtesady P, et al. Cause, timing, and location of death in the Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg. 2012;144(4):907–914.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Anderson JB, Bates KE, et al. Development of a validated risk score for interstage death or transplant after stage I palliation for single-ventricle heart disease. J Thorac Cardiovasc Surg. 2020;160(4):1021–1030.
   PubMedGoogle Scholar